Organisation: ECsens
Position: CTO
Point-of-care diagnostic platforms
During the first COVID-19 lockdown, ECsens prepared efforts to use their system for detection of individual biomakers to detect SARS-CoV-2 particles. Development of the QoroNano system started in 2020 and is expected to complete soon. Strategies for beyond COVID will also be discussed in this presentation.
Biography
Dr Pepijn Beekman did his BSc (Advanced Technology) and MSc (Nanotechnology) at the University of Twente (UT) and obtained his PhD degree from the Laboratory of Organic Chemistry at Wageningen University, where he developed biosensors for cancer diagnostics in collaboration with MCBP, NE and AMBER at UT. Results from this research were patented and together with dr. Dilu Mathew, he founded the company ECsens in 2019. ECsens (pronounced “easy sense”) develops nano-ElectroChemistry based lab-on-a-chip platforms for a range of applications, currently focusing on COVID-19 to demonstrate the concept. The company won i.a. the UT Challenge, 4TU Impact Finals and was in the top 20 of academic startups in 2020.
